Autobahn Therapeutics is developing orally administered small molecule prodrugs using a brain-targeting chemistry platform to create tailored therapies for neuropsychiatric and neuroimmunologic disorders. Their approach focuses on restoring brain health by leveraging validated human biology and biomarker-driven development to address the progressive nature of these debilitating conditions.
Funding
$214.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NMFounders
Product
Problem
Central nervous system (CNS) disorders, including neuropsychiatric and neuroimmunologic conditions, often follow a progressive course, leading to debilitating effects on patients' lives. Current treatments may not adequately address the underlying causes or restore optimal brain health, leaving a significant unmet need for more effective therapies.
Solution
Autobahn Therapeutics is developing a new generation of regenerative medicines for the brain, designed to restore brain health and improve the lives of individuals affected by CNS disorders. Their approach utilizes a brain-targeting chemistry platform to create orally administered small molecule prodrugs with tailored distribution profiles. By focusing on validated human biology and employing biomarker-driven development strategies, Autobahn aims to create therapies that address the progressive nature of these conditions and enable patients to live fuller lives.
Target Audience
The primary target audience includes individuals affected by CNS disorders, such as neuropsychiatric and neuroimmunologic conditions, as well as healthcare professionals and researchers seeking innovative therapies for these debilitating conditions.
Features
- Brain-targeting chemistry platform for creating orally administered small molecule prodrugs.
- Tunable ratios of central vs. peripheral exposure to match disease pathophysiology.
- Focus on validated human biology, leveraging established clinical precedence and human genetics.
- Biomarker-driven development strategies to demonstrate on-target/on-tissue activity.